Edition:
United States

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.40USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.40
Open
$4.45
Day's High
$4.50
Day's Low
$4.40
Volume
6,437
Avg. Vol
20,242
52-wk High
$8.55
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 07:00am EST 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

Kamada announces CFO transition
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Kamada Ltd :Kamada announces CFO transition.Kamada Ltd - Gil Efron, (deputy CEO) & Chief Financial Officer (CFO), recently informed company of his plan to leave at end of year.Kamada Ltd - Chaime Orlev will succeed as CFO, effective January 1, 2018.  Full Article

Kedrion, Kamada win FDA approval for rabies treatment
Friday, 25 Aug 2017 07:00am EDT 

Aug 25 (Reuters) - Kamada Ltd :Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection.Kedrion biopharma and kamada receive fda approval of kedrab™ for post-exposure prophylaxis against rabies infection.Kamada ltd - ‍kedrab will launch in u.s. In early 2018​.Kamada ltd - ‍revenues from the product are not included in guidance of reaching $100 million in total revenue in 2017​.  Full Article

Kamada Q2 earnings per share $0.13
Tuesday, 1 Aug 2017 06:30am EDT 

Aug 1 (Reuters) - Kamada Ltd ::Kamada reports financial results for second quarter and first six months of 2017.Q2 earnings per share $0.13.Sees FY 2017 revenue $100 million.Q2 revenue rose 71 percent to $33 million.Qtrly total revenues were $32.5 million, a 71% increase from $19.1 million reported in q2 of 2016.Kamada Ltd sees FY proprietary products revenues between $76 and $78 million and distributed products revenues between $22 and $24 million.Kamada Ltd - as of June 30, 2017, co had cash, cash equivalents and short term investments of $26.9 million.Qtrly earnings per share $0.13.Qtrly adjusted net income was $5.1 million.  Full Article

Kamada announces pricing of public offering of ordinary shares
Friday, 28 Jul 2017 09:27am EDT 

July 28 (Reuters) - Kamada Ltd :Kamada Ltd - pricing of 3.33 million of its ordinary shares at a price of $4.50 per share.  Full Article

Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin
Thursday, 22 Jun 2017 07:00am EDT 

June 22 (Reuters) - Kamada Ltd :Kamada announces withdrawal of European Marketing Authorization application for inhaled ALPHA-1 antitrypsin for treatment of ALPHA-1 antitrypsin deficiency disease.Kamada Ltd -following discussions with EMA, Kamada concluded that EMA does not view data submitted to date as sufficient for approval of MAA.Says Kamada intends to utilize data to be obtained from pivotal study to resubmit MAA to EMA.Kamada - is currently in advanced discussions with U.S. FDA to secure approval of IND this year to conduct U.S. phase 3 pivotal study of inhaled AAT for treatment of AATD that would begin in 2018.  Full Article

Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Kamada Ltd :Kamada receives additional milestone payment under glassia® exclusive supply and distribution agreement with shire.Kamada receives additional milestone payment under glassia® exclusive supply and distribution agreement with shire.Kamada Ltd - milestone payment was triggered by shire achieving a sales milestone for glassia in u.s.Kamada Ltd - recently shipped all of proprietary products-related revenues, totaling approximately $11.5 million, which were previously delayed from q1.Kamada Ltd - as detailed by kamada in its q1 financial results, revenues from shipment were shifted from q1 and will be recorded in q2.Kamada Ltd - announced receipt of an undisclosed additional milestone payment under supply and distribution agreement with shire for glassia.  Full Article

Kamada receives additional milestone payment from Shire PLC
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Kamada Ltd :Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire.Kamada Ltd - announced receipt of an undisclosed additional milestone payment under supply and distribution agreement with shire for Glassia.Kamada Ltd - milestone payment was triggered by shire achieving a sales milestone for Glassia in U.S..Kamada Ltd - recently shipped all of proprietary products-related revenues, totaling approximately $11.5 million, which were previously delayed from Q1.Kamada Ltd - as detailed by Kamada in its Q1 financial results, revenues from shipment were shifted from Q1 and will be recorded in Q2.  Full Article

Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment
Wednesday, 7 Jun 2017 07:00am EDT 

June 7 (Reuters) - Kamada Ltd :Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease.Kamada, Shire agreed INDA approved by U.S. FDA for phase 2/3 study evaluating alpha-1 antitrypsin for treatment of GVHD will be transferred to Kamada.Kamada will take full ownership and responsibility for clinical development of g1-aat iv in this indication.Kamada Ltd says Shire decided to transfer INDA to Kamada due to pipeline prioritization and slow recruitment rate in its current u.s. Study.Kamada will assume control of, and onward funding for full G1-AAT iv program.Kamada Ltd says intends to conduct an integrated clinical development program across both territories - u.s. And eu.Kamada Ltd says as result of this decision, current part 1 of phase 2/3 study conducted in u.s. Is being halted by shire.  Full Article

BRIEF-Kamada announces new supply agreement with international organization for KamRAB

* Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection